Isabelle A Leclercq

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1405865/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bile acids contribute to the development of non-alcoholic steatohepatitis in mice. JHEP Reports, 2022, 4, 100387.	2.6	28
2	Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. Nutrients, 2022, 14, 2707.	1.7	8
3	Fetuin-A in Activated Liver Macrophages Is a Key Feature of Non-Alcoholic Steatohepatitis. Metabolites, 2022, 12, 625.	1.3	8
4	Myosteatosis rather than sarcopenia associates with nonâ€alcoholic steatohepatitis in nonâ€alcoholic fatty liver disease preclinical models. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 144-158.	2.9	38
5	Rationale of adding muscle volume to muscle fat infiltration in the definition of an adverse muscle composition is unclear. JHEP Reports, 2021, 3, 100235.	2.6	1
6	Notch-IGF1 signaling during liver regeneration drives biliary epithelial cell expansion and inhibits hepatocyte differentiation. Science Signaling, 2021, 14, .	1.6	17
7	Critical Role of LSEC in Post-Hepatectomy Liver Regeneration and Failure. International Journal of Molecular Sciences, 2021, 22, 8053.	1.8	20
8	Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity. Journal of Hepatology, 2021, 75, 292-301.	1.8	68
9	Selective HIF stabilization alleviates hepatocellular steatosis and ballooning in a rodent model of 70% liver resection. Clinical Science, 2021, 135, 2285-2305.	1.8	5
10	Inflammationâ€induced cholestasis in cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 70-90.	2.9	24
11	Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease. International Journal of Molecular Sciences, 2021, 22, 12687.	1.8	10
12	Bile Acid Dysregulation Is Intrinsically Related to Cachexia in Tumor-Bearing Mice. Cancers, 2021, 13, 6389.	1.7	4
13	<i>Kras</i> and <i>Lkb1</i> mutations synergistically induce intraductal papillary mucinous neoplasm derived from pancreatic duct cells. Gut, 2020, 69, 704-714.	6.1	27
14	Insights into tissue microstructure using a double diffusion encoding sequence on a clinical scanner: Validation and application to experimental tumor models. Magnetic Resonance in Medicine, 2020, 83, 1263-1276.	1.9	7
15	Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH. Laboratory Investigation, 2020, 100, 147-160.	1.7	35
16	Digital Image Analysis of Picrosirius Red Staining: A Robust Method for Multi-Organ Fibrosis Quantification and Characterization. Biomolecules, 2020, 10, 1585.	1.8	33
17	Defective gut adaptive immunity during early alcoholic liver disease. Journal of Hepatology, 2020, 73, S185-S186.	1.8	0
18	Alterations in bile acids and TGR5 activation in non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, 594	1.8	0

#	Article	IF	CITATIONS
19	Hepatic NAPE-PLD Is a Key Regulator of Liver Lipid Metabolism. Cells, 2020, 9, 1247.	1.8	17
20	Double Diffusion Encoding for Probing Radiationâ€Induced Microstructural Changes in a Tumor Model: A Proofâ€ofâ€Concept Study With Comparison to the Apparent Diffusion Coefficient and Histology. Journal of Magnetic Resonance Imaging, 2020, 52, 941-951.	1.9	1
21	Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes, 2020, 12, 1782157.	4.3	83
22	New insights in acetaminophen toxicity: HMGB1 contributes by itself to amplify hepatocyte necrosis in vitro through the TLR4-TRIF-RIPK3 axis. Scientific Reports, 2020, 10, 5557.	1.6	14
23	IGF2 mRNA Binding Protein 2 Transgenic Mice Are More Prone to Develop a Ductular Reaction and to Progress Toward Cirrhosis. Frontiers in Medicine, 2019, 6, 179.	1.2	12
24	Associating liver partition and portal vein ligation for staged hepatectomy: establishment of an an animal model with insufficient liver remnant. Laboratory Investigation, 2019, 99, 698-707.	1.7	6
25	Hypoxia protects the liver from Small For Size Syndrome: A lesson learned from the associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure in rats. American Journal of Transplantation, 2019, 19, 2979-2990.	2.6	14
26	Invasive Ductular Reaction Operates Hepatobiliary Junctions upon Hepatocellular Injury in Rodents and Humans. American Journal of Pathology, 2019, 189, 1569-1581.	1.9	19
27	Deficient ILâ€6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis. Hepatology Communications, 2019, 3, 867-882.	2.0	24
28	Comparison of the Opn-CreER and Ck19-CreER Drivers in Bile Ducts of Normal and Injured Mouse Livers. Cells, 2019, 8, 380.	1.8	12
29	Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury. Journal of Hepatology, 2019, 70, 1180-1191.	1.8	61
30	Emerging awareness on the importance of skeletal muscle in liver diseases: time to dig deeper into mechanisms!. Clinical Science, 2019, 133, 465-481.	1.8	51
31	Does haemophilia slow down the development of liver fibrosis?. Haemophilia, 2019, 25, e32-e35.	1.0	3
32	Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. Hepatology, 2019, 69, 2241-2257.	3.6	227
33	Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis. Laboratory Investigation, 2019, 99, 4-16.	1.7	22
34	Mouse models of nonâ€alcoholic steatohepatitis: A reflection on recent literature. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1312-1320.	1.4	34
35	Tumoral response and tumoral phenotypic changes in a rat model of diethylnitrosamine-induced hepatocellular carcinoma after salirasib and sorafenib administration. OncoTargets and Therapy, 2018, Volume 11, 7143-7153.	1.0	6
36	Liver Regeneration: Different Sub-Populations of Parenchymal Cells at Play Choreographed by an Injury-Specific Microenvironment. International Journal of Molecular Sciences, 2018, 19, 4115.	1.8	20

#	Article	IF	CITATIONS
37	TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. International Journal of Molecular Sciences, 2018, 19, 817.	1.8	34
38	Chronic liver injury promotes hepatocarcinoma cell seeding and growth, associated with infiltration by macrophages. Cancer Science, 2018, 109, 2141-2152.	1.7	21
39	The newâ€generation panâ€peroxisome proliferatorâ€activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. Hepatology Communications, 2017, 1, 524-537.	2.0	97
40	Defective adaptive thermogenesis contributes to metabolic syndrome and liver steatosis in obese mice. Clinical Science, 2017, 131, 285-296.	1.8	32
41	Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice. Scientific Reports, 2017, 7, 8268.	1.6	33
42	Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. Obesity, 2017, 25, 155-165.	1.5	40
43	Upstream regulators of hepatic Wnt/βâ€catenin activity control liver metabolic zonation, development, and regeneration. Hepatology, 2016, 64, 1361-1363.	3.6	7
44	Colonic acetate in obesity: location matters!. Clinical Science, 2016, 130, 2083-2086.	1.8	7
45	Experimental models of liver fibrosis. Archives of Toxicology, 2016, 90, 1025-1048.	1.9	243
46	Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies. PLoS ONE, 2016, 11, e0162286.	1.1	25
47	Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling. Aging, 2016, 9, 98-113.	1.4	36
48	Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome. Clinical Science, 2015, 129, 933-949.	1.8	74
49	Hepatic Stellate Cells Improve Engraftment of Human Primary Hepatocytes: A Preclinical Transplantation Study in an Animal Model. Cell Transplantation, 2015, 24, 2557-2571.	1.2	19
50	Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development. Journal of Clinical and Translational Hepatology, 2015, 3, 53-66.	0.7	130
51	Next generation of ALDH substrates and their potential to study maturational lineage biology in stem and progenitor cells. American Journal of Physiology - Renal Physiology, 2015, 308, G573-G578.	1.6	17
52	Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. Journal of Clinical Investigation, 2015, 125, 3891-3903.	3.9	175
53	Yin Yang 1 and farnesoid X receptor: a balancing act in non-alcoholic fatty liver disease?. Gut, 2014, 63, 1-2.	6.1	22
54	Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed <i>foz/foz</i> mice. Clinical Science, 2014, 127, 507-518.	1.8	21

#	Article	IF	CITATIONS
55	Liver and systemic insulin resistance. Hepatology, 2014, 60, 1113-1114.	3.6	8
56	The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis. Journal of Lipid Research, 2014, 55, 1087-1097.	2.0	42
57	Adipose tissues as endocrine target organs. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 545-558.	1.0	58
58	Reply. Gastroenterology, 2013, 145, 255-256.	0.6	3
59	Prometheus' little helper, a novel role for fibroblast growth factor 15 in compensatory liver growth. Journal of Hepatology, 2013, 59, 1121-1123.	1.8	9
60	Impact of PPAR-α induction on glucose homoeostasis in alcohol-fed mice. Clinical Science, 2013, 125, 501-511.	1.8	12
61	Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology, 2013, 57, 1793-1805.	3.6	74
62	Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. Hpb, 2013, 15, 858-864.	0.1	50
63	Participation of liver progenitor cells in liver regeneration: lack of evidence in the AAF/PH rat model. Laboratory Investigation, 2012, 92, 72-81.	1.7	15
64	Proâ€oxidants or antiâ€oxidant defenses? Which one to blame in nonâ€alcoholic steatohepatitis pathogenesis?. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1651-1653.	1.4	1
65	Liver Progenitor Cells Yield Functional Hepatocytes in Response to Chronic Liver Injury in Mice. Gastroenterology, 2012, 143, 1564-1575.e7.	0.6	305
66	Enhanced choline metabolism in a rodent rhabdomyosarcoma model: correlation between RT-PCR and translational 3 T H-MRS. Magnetic Resonance Imaging, 2012, 30, 1010-1016.	1.0	0
67	Ras inhibition in hepatocarcinoma by <i>S</i> â€ <i>trans</i> â€ <i>trans</i> â€farnesylthiosalicyclic acid: Association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. Molecular Carcinogenesis, 2012, 51, 816-825.	1.3	7
68	Successful isolation of liver progenitor cells by aldehyde dehydrogenase activity in naÃ ⁻ ve mice. Hepatology, 2012, 55, 540-552.	3.6	53
69	Embryonic Ductal Plate Cells Give Rise to Cholangiocytes, Periportal Hepatocytes, and Adult Liver Progenitor Cells. Gastroenterology, 2011, 141, 1432-1438.e4.	0.6	235
70	Kupffer Cells Influence Parenchymal Invasion and Phenotypic Orientation, but Not the Proliferation, of Liver Progenitor Cells in a Murine Model of Liver Injury. American Journal of Pathology, 2011, 179, 1839-1850.	1.9	62
71	Hepatic endoplasmic reticulum stress in obesity: Deeper insights into processes, but are they relevant to nonalcoholic steatohepatitis?. Hepatology, 2011, 54, 2261-2266.	3.6	5
72	Animal models for the study of hepatic fibrosis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 319-333.	1.0	134

#	Article	lF	CITATIONS
73	Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a highâ€fat diet. FASEB Journal, 2011, 25, 4301-4311.	0.2	101
74	Central Apelin Controls Glucose Homeostasis <i>via</i> a Nitric Oxide-Dependent Pathway in Mice. Antioxidants and Redox Signaling, 2011, 15, 1477-1496.	2.5	66
75	Hepatic n-3 Polyunsaturated Fatty Acid Depletion Promotes Steatosis and Insulin Resistance in Mice: Genomic Analysis of Cellular Targets. PLoS ONE, 2011, 6, e23365.	1.1	83
76	Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chemico-Biological Interactions, 2010, 183, 238-248.	1.7	20
77	Clodronate liposomes: All sites of injection are not equal. Hepatology, 2010, 51, 721-722.	3.6	9
78	NFκB, cytokines, TLR 3 and 7 expression in human endâ€stage HCV and alcoholic liver disease. European Journal of Clinical Investigation, 2010, 40, 575-584.	1.7	28
79	Kupffer cell activation is a causal factor for hepatic insulin resistance. American Journal of Physiology - Renal Physiology, 2010, 298, G107-G116.	1.6	204
80	Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*. Journal of Biological Chemistry, 2010, 285, 33652-33661.	1.6	313
81	Early Detection of Steatohepatitis in Fatty Rat Liver by Using MR Elastography. Radiology, 2009, 253, 90-97.	3.6	134
82	Relation between liver progenitor cell expansion and extracellular matrix deposition in a CDE-induced murine model of chronic liver injury. Hepatology, 2009, 49, 1625-1635.	3.6	143
83	Adiponectin in nonâ€alcoholic steatohepatitis: An ideal culprit, but what are the proofs of its guilt?. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1584-1586.	1.4	1
84	Prevention of steatohepatitis by pioglitazone: Implication of adiponectin-dependent inhibition of SREBP-1c and inflammation. Journal of Hepatology, 2009, 50, 489-500.	1.8	34
85	The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis. Current Opinion in Clinical Nutrition and Metabolic Care, 2009, 12, 404-411.	1.3	43
86	Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. International Journal of Molecular Medicine, 2009, 24, 171-80.	1.8	59
87	Nonalcoholic fatty liver disease: the potential role of nutritional management. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 766-773.	1.3	28
88	Nuclear factor-kappa B is constitutively activated in peritoneal endometriosis. Molecular Human Reproduction, 2007, 13, 503-509.	1.3	132
89	NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. Journal of Hepatology, 2007, 46, 304-313.	1.8	44
90	Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. Journal of Hepatology, 2007, 47, 142-156.	1.8	299

#	Article	IF	CITATIONS
91	ADAM metallopeptidase with thrombospondin type 1 motif 2 inactivation reduces the extent and stability of carbon tetrachloride-induced hepatic fibrosis in mice. Hepatology, 2007, 46, 1620-1631.	3.6	56
92	Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARÎ ³ agonist pioglitazone. Laboratory Investigation, 2007, 87, 56-65.	1.7	86
93	Role of signal transducer and activator of transcription 3 in liver fibrosis progression in chronic hepatitis C-infected patients. Laboratory Investigation, 2007, 87, 173-181.	1.7	18
94	Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. Cancer Science, 2007, 98, 1831-1839.	1.7	12
95	Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice. International Journal of Molecular Medicine, 2007, 19, 105-12.	1.8	26
96	Pathogenesis of steatohepatitis: insights from the study of animal models. Acta Gastro-Enterologica Belgica, 2007, 70, 25-31.	0.4	6
97	Defective hepatic regeneration after partial hepatectomy in leptin-deficient mice is not rescued by exogenous leptin. Laboratory Investigation, 2006, 86, 1161-1171.	1.7	44
98	Hépatopathie non alcoolique: de la stéatose à la cirrhose. Acta Endoscopica, 2006, 36, 299-314.	0.0	1
99	COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology, 2006, 43, 826-836.	3.6	154
100	Blunted DNA synthesis and delayed S-phase entry following inhibition of Cdk2 activity in the regenerating rat liver. Laboratory Investigation, 2005, 85, 562-571.	1.7	8
101	Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. Journal of Hepatology, 2005, 43, 687-695.	1.8	26
102	Disrupted NF-κB activation after partial hepatectomy does not impair hepatocyte proliferation in rats. World Journal of Gastroenterology, 2005, 11, 7345.	1.4	10
103	Administration of the potent PPAR? agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology, 2004, 39, 1286-1296.	3.6	343
104	Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice. Journal of Hepatology, 2004, 41, 926-934.	1.8	193
105	Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis?. Clinical Science, 2004, 106, 235-237.	1.8	31
106	Low-dose TNF-α protects against hepatic ischemia-reperfusion injury in mice: Implications for preconditioning. Hepatology, 2003, 37, 118-128.	3.6	106
107	Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology, 2003, 38, 123-132.	3.6	420
108	Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology, 2003, 124, 1451-1464.	0.6	99

#	Article	IF	CITATIONS
109	Oxidative stress, KLF6 and transforming growth factor-β up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. Journal of Hepatology, 2003, 39, 538-546.	1.8	129
110	Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Journal of Hepatology, 2003, 39, 756-764.	1.8	215
111	Leptin is essential for the hepatic fibrogenic response to chronic liver injury. Journal of Hepatology, 2002, 37, 206-213.	1.8	366
112	Liver regeneration in obese mice with fatty livers: Does the impairment have relevance for other types of fatty liver disease?. Hepatology, 2002, 35, 731-731.	3.6	12
113	II. Cytochrome <i>P</i> -450 enzymes and oxidative stress. American Journal of Physiology - Renal Physiology, 2001, 281, G1135-G1139.	1.6	305
114	CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. Journal of Clinical Investigation, 2000, 105, 1067-1075.	3.9	654
115	Constitutive and Inducible Expression of Hepatic CYP2E1 in Leptin-deficient ob/ob Mice. Biochemical and Biophysical Research Communications, 2000, 268, 337-344.	1.0	66
116	The compensatory hyperplasia (liver regeneration) following ligation of a portal branch is initiated before the atrophy of the deprived lobes. Journal of Hepatology, 2000, 32, 940-945.	1.8	29
117	Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity. British Journal of Nutrition, 1999, 82, 257-262.	1.2	16
118	Altered Expression of HepaticCYP2E1andCYP4Ain Obese, Diabeticob/obMice, andfa/faZucker Rats. Biochemical and Biophysical Research Communications, 1999, 255, 300-306.	1.0	105
119	Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress*. Clinical Pharmacology and Therapeutics, 1998, 64, 144-149.	2.3	76
120	Estimation of chlorzoxazone hydroxylase activity in liver microsomes and of the plasma pharmacokinetics of chlorzoxazone by the same high-performance liquid chromatographic method. Journal of Chromatography A, 1998, 828, 291-296.	1.8	28
121	Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. Journal of Hepatology, 1998, 28, 410-416.	1.8	58
122	Relevance of the CDE and DDC Mouse Models to Study Ductular Reaction in Chronic Human Liver Diseases. , 0, , .		4